Youth-Onset Type 2 Diabetes and Heart Disease: The Young at Heart Prospective Cohort Study
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · NCT06730113
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 12–25 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 930
- US sites recruiting
- 2
- Study start
- March 12, 2025
- Record last updated
- September 17, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Background
Type 2 diabetes is a disease that affects blood sugar levels. Complications can include heart and blood vessel (vascular) diseases. Rates of type 2 diabetes have tripled in children and young adults over the last 40 years. Vascular diseases are also increasing in young people.
Objective
To learn more about factors, including type 2 diabetes, that may cause vascular disease in young people.
Eligibility
People aged 12 to 25 years who (1) have type 2 diabetes; (2) are overweight but not diabetic; (3) or are lean and healthy. Biological parents are also needed.
Design
Young participants will visit the NIH clinic once a year for up to 25 years. Each visit will take 4 days. Before each visit, participants will wear devices to track their sleep, activity, and blood sugar levels for 7 to 10 days.
At each visit, participants will have tests including:
Samples: They will provide blood, urine, and stool samples.
Heart: They will ride a stationary bike for 6 minutes with stickers applied to their chest.
Scans: They will lie on a bed that slides into a tube; the machine will take pictures of the inside of their body.
Energy: They will wear a hood over their head to measure the air they breathe.
Social stress: They will give a speech for 10 minutes to show their body s response to stress.
Glucose: They will drink a sweet drink to see how their blood sugar changes.
Biological parents will have 1 study visit. They will have blood tests. They will fill in questionnaires about their lifestyle and stress.
...
Conditions: Obesity; Type 2 Diabetes
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
- INCLUSION CRITERIA:
To be eligible to participate in this study, an individual must meet the following criteria according to their group:
Four categories of participants will be included in this study and the inclusion criteria for each group are given below:
- Participants with Y-T2DM
1a.Age 12-25 years
1b.Type 2 diabetes mellitus as defined by fasting blood glucose >= 126 mg/dL OR postprandial blood sugar >= 200 mg/dL OR Hemoglobin A1c >= 6.5% per American Diabetes Association Criteria and one element from the medical history consistent with ADA or AAP guidelines including: family history of diabetes and obesity, maternal or personal history of gestational diabetes, high-risk race and ethnicity, history of cardiovascular disease, hypertension, dyslipidemia, polycystic ovary syndrome, physical inactivity, other clinical conditions associated with insulin resistance (e.g. severe obesity, acanthosis nigricans, prediabetes), small or large for gestational age birth weight, history of breastfeeding, gestational history of illicit drugs including alcohol, smoking OR documentation of type 2 diabetes diagnosed at \<=25 years of age with verified medical history (as above).
- Youth with overweight/ obesity (Y-OW)
2a. Age 12-25 years
2b. For participants \< 18 years of age, BMI >= 85th percentile (overweight) and >= 95th percentile (obesity) for age and sex OR
2c. For participants >= 18 years of age, BMI >=25\<30 kg/m\^2 (overweight) or >=30 kg/m\^2 (obesity)
2d. Participants with obesity may have a diagnosis of prediabetes, defined as fasting blood glucose 100-125 mg/dL OR postprandial blood sugar 140-199 mg/dL OR HbA1c 5.7-6.4 percent (either during testing at NIH or as previously documented on outside medical record).
- Healthy control lean participants (Y-Lean)
3a. Age 12-25 years
3b. For participants \< 18 years of age, BMI \<= 85th percentile for age and sex OR
3c. For participants >=18 years of age, BMI 18-24.99 kg/m\^2.
3d. HbA1c \<5.7 percent (either during testing at NIH or as previously documented on outside medical record).
- Biological parents of Y-T2DM, Y-OW and Y-Lean participants
4a. Biological parent of enrolled Y-T2DM, Y-OW and Y-Lean by self-report.
EXCLUSION CRITERIA
An individual who meets any of the following criteria for their specific group will be excluded from participation in this study:
- Y-T2DM, Y-OW and Y-Lean Participants:
1a. Type 1 diabetes or the presence of >2 diabetes auto-antibodies (e.g., GAD-65, IA-2 antigen, Zinc transporter 8 autoantibodies).
- b. Medical, psychiatric or cognitive disorders that will, in the opinion of the investigators, limit the subject s ability to comply with study procedures (specific obesity-related comorbidities are explicitly permitted, including hypertension, hyperlipidemia, obstructive sleep apnea and non-alcoholic steatohepatitis).
1c. Serious medical illnesses or diseases thought to alter metabolism (including moderate to severe renal disease (\< 30 mL/min/1.73m\^2), congenital heart disease, Cushing s syndrome, cancer, or other metabolic diseases associated with diabetes or excess weight).
1d. For participants enrolled at the NIH, dietary allergies, intolerances or eating patterns that would preclude them from consuming metabolic meals.
1e. Unwilling to comply with all study procedures or to adhere to Lifestyle Considerations throughout study duration.
1f. Pregnancy at the time of the screening visit.
1g. Clinically significant anemia OR Hematocrit below the lower limit of normal for age and sex cutoffs.
- h. For Y-OW Participants- Meet lab and medical history criteria for Y-T2DM as described in inclusion criterion 1b above.
- Y-Lean participants:
In addition to the above exclusion criteria, any Y-Lean participant who meets any of the following additional criteria will be excluded from the study:
2a. Current use of prescription or non-prescription medication. Certain exceptions are permitted, including topical medications, vitamins, and hormonal contraceptives. Other medications may be permitted at the discretion of the investigators.
2b. Recent (past 2 months) use of drugs or supplements that alter glucose or lipid metabolism (e.g., niacin, fish oil, red yeast rice)
2c. History of diabetes or abnormal glucose tolerance
2d.. Abnormal screening labs, including the following:
i) ALT or AST >2 times the upper limit of normal
ii) Glycosuria
iii) Low eGFR (\<90 mL/min/1.73m\^2)Any other abnormality that, in the opinion of the investigator, will increase risk to the subject from participation, or interfere with interpretation of study data
2e. Meet lab and medical history criteria for Y-T2DM as described in inclusion criterion 1b above.
- Biological Parents
-No Exclusion Criteria
Recruiting US locations
Children's National Hospital (CNH)
Washington D.C., DC 20010
Site contact: Doris Estrada · 202-476-2121 · destrada@childrensnational.org
National Institutes of Health Clinical Center
Bethesda, MD 20892
Site contact: Stephanie Chung, M.D. · 240-479-8137 · stephanie.chung@nih.gov
Study contacts (from the official record)
- Lilian S Mabundo · (240) 383-9379 · lilian.mabundo@nih.gov
- Stephanie T Chung, M.D. · (240) 479-8137 · stephanie.chung@nih.gov
Similar studies in District of Columbia
All weight loss studies in District of Columbia →- Recruiting
The RESET System Pivotal Clinical Trial (Protocol Revision K)
Morphic Medical Inc.
- Location
- Washington D.C., DC + 25 other US sites
- Eligibility basics
- Ages 22–65
- RecruitingPhase 3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Hoffmann-La Roche
- Location
- Washington D.C., DC + 44 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
Novo Nordisk A/S
- Location
- Washington D.C., DC + 32 other US sites
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteers
Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
National Heart, Lung, and Blood Institute (NHLBI)
- Location
- Washington D.C., DC + 1 other US site
- Eligibility basics
- Ages 1–100